Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
5.09
-0.33 (-6.01%)
May 9, 2025, 4:00 PM - Market closed
Vir Biotechnology Employees
Vir Biotechnology had 408 employees as of December 31, 2024. The number of employees decreased by 179 or -30.49% compared to the previous year.
Employees
408
Change (1Y)
-179
Growth (1Y)
-30.49%
Revenue / Employee
$51,130
Profits / Employee
-$1,415,806
Market Cap
708.47M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
VIR News
- 10 hours ago - Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study - Business Wire
- 1 day ago - Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment - Seeking Alpha
- 1 day ago - Vir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results - Business Wire
- 9 days ago - Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025 - Business Wire
- 15 days ago - Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025 - Business Wire
- 7 weeks ago - Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results - PRNewsWire
- 2 months ago - Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta - Business Wire